KIT2014

PreclinicalSmall molecule

KIT2014 is one of 5 small molecule programs targeting Chronic Obstructive Pulmonary Disease (COPD). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary Disease (COPD)Not yet recruiting

Chronic Obstructive Pulmonary Disease (COPD)Preclinical

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Chronic Obstructive Pulmonary Disease (COPD)

#DrugCompanyPhaseTrials

Tezspire

AstraZeneca

Phase 3

2 2

AZD6793

AstraZeneca

Phase 2

1 3

Trimethoprim-Sulfamethoxazole

Astellas

Preclinical

1 4

BBT002

BBambusa Therapeutics

Phase 1

1 5

KIT2014

KKither Biotech Srl

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Chronic Obstructive Pulmonary Disease (COPD)

NCT07668518

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease (COPD)1 trial

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Ranging, Phase 1b/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics and Early Efficacy of Inhaled KIT2014 Over 7 Days of Treatment in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Recruiting·KKither Biotech Srl·Preclinical·NCT07668518·36 enrolled

Unspecified1 trial

A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of KIT2014 in Healthy Subjects

Completed·KKither Biotech Srl·Phase 1·NCT06659757·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for KIT2014. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KIT2014 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KIT2014. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kither Biotech Srl company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKither Biotech Srl

KIT2014

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease (COPD)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News